Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 20/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14738108 | 0.92 | KIT (1.00) | KIT | |
| SCHEMBL14738513 | 0.90 | KIT (1.00) | KIT | |
| SCHEMBL14739527 | 0.90 | KIT (1.00) | KIT | |
| SCHEMBL14739237 | 0.90 | KIT (1.00) | KIT | |
| SCHEMBL14738823 | 0.90 | KIT (1.00) | KIT | |
| SCHEMBL14750968 | 0.89 | KIT (0.89) | KIT | |
| SCHEMBL14738798 | 0.89 | KIT (1.00) | KIT | |
| SCHEMBL14739982 | 0.89 | KIT (0.84) | KIT | |
| SCHEMBL14738950 | 0.89 | KIT (1.00) | KIT | |
| SCHEMBL14742316 | 0.87 | KIT (0.89) | KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751102-B1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-03-27 | — | — | EP | disclosed |
| US-9199981-B2 | Compounds and compositions as C-kit kinase inhibitors | NOVARTIS AG (CH) | 2015-12-01 | — | — | US | disclosed |
| EP-2751102-A1 | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033070-A1 | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059846-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059846-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | KIT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.